Livongo Health Inc. has filed a registration statement with the U.S. Securities and Exchange Commission to offer 10.7 million shares of its common stock to the public.

Livongo will grant underwriters a 30-day option to purchase up to an additional 1.605 million shares of common stock from Livongo. The IPO price is expected to be between $20 and $23 per share. Livongo has applied to be listed on the Nasdaq Global Select Market under the symbol LVGO.

Morgan Stanley, Goldman Sachs and J.P. Morgan Securities will serve as lead joint book-running managers for the proposed offering. Piper Jaffray and SVB Leerink will serve as lead co-managers and Canaccord Genuity, KeyBanc Capital Markets Inc. and Needham & Co. will serve as co-managers for the proposed offering.

Livongo, based in Mountain View, Calif., previously raised $240 million through multiple rounds of VC investment. Investors include Kleiner Perkins, General Catalyst, Microsoft Corp. and Sapphire Ventures.

Last month, the digital-health startup co-founded by Chicagoan Glenn Tullman, former CEO of Allscripts, filed to make an IPO that is expected to value the company at more than $1 billion. He co-founded the business in 2012 to provide glucose monitors and test strips for diabetes. It has since become a provider of wearable tech to monitor other conditions, including high blood pressure and excess weight. Tullman turned over the reins of the company in December to veteran healthcare technology executive Zane Burke.

Through six rounds of funding, Livongo has raised $235 million, according to Crunchbase.